Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Selasa, 08 April 2025 - 03:52:58 Wib
Globenewswire

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Selasa, 08 April 2025 - 03:50:43 Wib
Globenewswire

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

Selasa, 01 April 2025 - 22:51:43 Wib
Globenewswire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Jumat, 28 Maret 2025 - 21:48:52 Wib
Globenewswire

Teva Releases Q1 2025 Aide Memoire

Jumat, 28 Maret 2025 - 21:46:56 Wib
Globenewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Rabu, 26 Februari 2025 - 11:16:38 Wib
Globenewswire

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Sabtu, 22 Februari 2025 - 14:30:00 Wib
Globenewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Rabu, 12 Februari 2025 - 18:30:00 Wib
Globenewswire

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Rabu, 19 Februari 2025 - 22:52:35 Wib
Globenewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Selasa, 18 Februari 2025 - 18:30:00 Wib
Globenewswire

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Rabu, 29 Januari 2025 - 19:30:00 Wib
Globenewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Senin, 27 Januari 2025 - 18:30:00 Wib
Globenewswire

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in Major Parts of Europe and in Israel

Senin, 13 Januari 2025 - 13:30:00 Wib
Globenewswire

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Selasa, 24 Desember 2024 - 11:36:00 Wib
Globenewswire

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Sabtu, 21 Desember 2024 - 11:20:28 Wib
Globenewswire

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Selasa, 17 Desember 2024 - 20:30:00 Wib
Globenewswire

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Rabu, 11 Desember 2024 - 20:07:02 Wib
Globenewswire

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Jumat, 06 Desember 2024 - 14:23:23 Wib
Globenewswire

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Rabu, 04 Desember 2024 - 14:30:00 Wib
Globenewswire

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Selasa, 26 November 2024 - 06:09:27 Wib
Globenewswire

Teva to Present at the Jefferies London Healthcare Conference

Sabtu, 09 November 2024 - 05:00:00 Wib
Globenewswire

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Sabtu, 02 November 2024 - 03:59:12 Wib
Globenewswire

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as Well as

Sabtu, 02 November 2024 - 03:58:04 Wib
Globenewswire

Teva Statement on European Commission Decision; Company to Appeal

Kamis, 31 Oktober 2024 - 18:30:00 Wib
Globenewswire

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Selasa, 22 Oktober 2024 - 18:30:00 Wib